Tempest Therapeutics, Inc. (TPST): Submission of Matters to a Vote of Security Holders
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. Item 8.01 Other Events. On August 17, 2026, Tempest Therapeutics, Inc. (the “Company”) called to order its
How this was made
The 30-second read
Why it matters
The proposal requires approval by holders of at least 75% of votes entitled in an annual director election; the meeting was adjourned due to insufficient votes at the time, and will reconvene on September 15, 2026 at 12:00 p.m. ET via webcast.
Market read
This is a governance-timeline update that can affect control expectations and proxy positioning ahead of the September 15 vote.
What to watch
Traders may be underweighting proxy solicitation dynamics (Sodali & Co. engagement) and the possibility that the vote threshold is close, which can drive late-cycle positioning into the reconvened meeting.
Background
Tempest called a reconvened special meeting originally convened and adjourned on July 27, 2026 to vote on a Certificate of Amendment to its Restated Certificate of Incorporation.
Ticker impact
Tempest Therapeutics adjourned and will reconvene its special stockholder meeting to vote on a charter amendment changing supermajority voting requirements.
Near-term volatility risk around vote timing and proxy dynamics; direction uncertain without vote outcome or investor sentiment details.
This is a primary SEC disclosure of a reconvened special meeting and unchanged proposal terms, which can affect perceived control and deal/financing optionality, but it does not provide the vote result or quantify expected economic impact.
Market effects
Limited sector read-through, as the event is company-specific governance mechanics rather than clinical or regulatory developments.
Minimal, as it is a Nasdaq-listed US small-cap corporate action with no stated cross-border operational impact.
Low, no international counterparties or global regulatory actions are mentioned.
Counterpoint
The adjournment may simply reflect administrative timing to broaden participation, not a substantive loss of support for the amendment.
Key entities
- issuerTempest Therapeutics, Inc.
Nasdaq-listed company filing the 8-K about the reconvened special stockholder meeting and the charter amendment vote.
- proxy_solicitation_firmSodali & Co.
Proxy solicitation firm engaged to help obtain adequate votes for the required quorum/approval.
